AtriCure director Regina Groves sells $288,070 of stock By Investing.com

Regina Groves, a director at AtriCure, Inc. (), sold 5,313 shares of the company’s common stock on September 11, 2026, for a total value of $288,070. The shares were sold at prices ranging from $54.09 to $54.38 each.

Following this transaction, Ms. Groves directly holds 34,546 shares of AtriCure common stock.

In other recent news, AtriCure Inc. reported second-quarter 2026 earnings that exceeded Wall Street expectations, with adjusted earnings of $0.18 per share compared to an anticipated loss of $0.01. Revenue also surpassed projections, reaching $153.6 million against an expected $151.84 million. Despite these strong results, the company’s outlook for the remainder of the year prompted some investor caution. In analyst activity, Needham raised its price target for AtriCure to $64, maintaining a Buy rating, citing the company’s BoxX-NoAF trial as a key factor. Piper Sandler also increased its price target to $60, highlighting a new quality measure by the Society of Thoracic Surgeons as a catalyst for AtriCure’s open ablation business. Similarly, BTIG raised its target to $55, referencing the potential impact of the new quality metric on the use of AtriCure’s Open Ablation products. These developments reflect a positive outlook from analysts based on recent initiatives and market dynamics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.